What is RCKT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.28B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RCKT?

P/E (TTM) is n/a and 52-week range is $2.42 to $5.45 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RCKT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RCKT?

The company profile lists net income (TTM) near $-20M, EPS (TTM) near $-0.18 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rocket Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cranbury, New Jersey, US, 109.2M shares outstanding, ISIN US77313F1066 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Rocket Pharmaceuticals Inc

$RCKT

Health Care · Biotechnology

IR Run Scenarios

$2.56

-2.66%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Employees

202

Website

www.rocketpharma.com/

IPO

2015-02-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)